CRISPR Screening Services
CRISPR Screening Services Horizon offers comprehensive CRISPR screening services from screen design and cell line selection to sophisticated bioinformatics analysis of the screen results. Our best-in-class CRISPR KO (knockout), CRISPRi (interference) and CRISPRa (activation) screening platforms can significantly advance our customers’ drug development programs by offering the highest quality and highest confidence in their…
CRISPR Screening Services
Horizon offers comprehensive CRISPR screening services from screen design and cell line selection to sophisticated bioinformatics analysis of the screen results. Our best-in-class CRISPR KO (knockout), CRISPRi (interference) and CRISPRa (activation) screening platforms can significantly advance our customers’ drug development programs by offering the highest quality and highest confidence in their screening results.
Data analysis services, including sample preparation, Next-Gen Sequencing, and hit calling, can be provided for users of Edit-R Lentiviral sgRNA Pooled Screening Libraries. Simply provide whole cell pellets for each of your samples and we’ll do the rest. We can also help with the NGS data analysis and hit calling for data created using the Edit-R Pooled sgRNA Indexing PCR and Sequencing Primer Kits.
Types of CRISPR Screen
Expertise includes whole-genome and custom targeted drug resistance and sensitivity screens, synthetic lethality target discovery screens and complex phenotypic screens using a FACS-based readout. We have optimized 50+ cell lines for CRISPR screening and have completed over 300 screens to date.
We offer a choice of CRISPR screen types depending on the expression effect you require:
- CRISPR KO screening with complete loss of gene expression provides the maximal window for phenotypic effect and high statistical power for hit discovery
- CRISPRi screening represses expression rather than completely knocking out the target gene and is ideally suited to study druggability and to evaluate the function of genes that when knocked-out are essential or that are amplified
- CRISPRa screening amplifies gene expression in its endogenous context and enables for the first time, to study activation-linked responses on a genome-wide level
- Dual CRISPRi & CRISPRa screening
Manipulating iPSCs with CRISPR – Functional knockouts, fluorescent tagging, and expression activation
This application note by Horizon Discovery presents the ability to modify the genome and modulate expression of genes within a human induced pluripotent stem (iPS) cell line with Dharmacon™ Edit-R CRISPR reagents.
Cell-based screening services from consultation to delivery
This brochure by Horizon Discovery presents their cell-based screening services, from consultation to delivery.
siRNA screening: Development of hit stratification strategies
In this poster, two strategies are compared for identification of high confidence hits: 1) a multiple reagent approach where two or more individual siRNAs induce the same phenotype and 2) a chemical modification approach where hit confirmation is achieved using pools of siRNA that contain specificity enhancing modifications.
CRISPR gene editing: Edit with confidence
This brochure by Horizon Discovery aims to help you maximize knockouts, minimize off-target effects with Edit-R™ reagents.
CRISPR-Cas9 screening for target identification
This application note by Horizon Discovery presents a method that adapted a pooled-based screening protocol, where lentivirus transduction delivers both the Cas9 endonuclease and the sgRNA to the cells.
Pooled and arrayed CRISPRko screens in primary human immune cells’ poster
This poster compares CRISPR screens on human immune cells carried out using a pooled or an arrayed platform.
RNA-based screens in primary human immune cells’ poster
Pooled CRISPR knockout screens in primary human T cells allow clinically relevant biological questions to be answered in a cellular context that is more relevant to the clinic. This poster investigates RNA-based screens in primary human immune cells.
Arrayed CRISPRko screening in primary human regulatory B cells
This application note by Horizon Discovery aims to demonstrate the full potential of arrayed CRISPRko screening in Bregs.
3D cell panel screens for drug discovery and development
In this application note, Horizon Discovery describes the development of a parallel 3D OncoSignature service that enables screening across a panel of 200 cell lines in a spheroid format. This application note also demonstrates the use of patient-derived organoids as a powerful secondary screening tool to validate the findings of a 2D and spheroid-based 3D screens in a more complex 3D model system.
Arrayed CRISPRko screening in primary human regulatory B cells
In this poster, Horizon Discovery demonstrates the full potential of arrayed CRISPRko screening in regulatory B cells (Bregs) and discusses how it has developed a co-culture assay where impaired proliferation of T cells acts as a functional readout of the suppressive nature of Bregs.
Video Guide: Advantages of Horizon's CRISPR-Cas9 Tools for Gene Editing
This video covers some of the many advantages of using Horizon Discovery's CRISPR-Cas9 tools for gene editing. These include speed, scalability, flexibility, and after-sales care.
Gene modulation in primary human immune cells: Successful strategies and applications for CRISPRko, RNAi and beyond
Watch this on-demand webinar to learn more about manipulating the genes within physiologically relevant human immune cells
Top new resources to advance your immuno-oncology research
Exclusive interviews, free downloads, the latest methods and much more to help support your immuno-oncology research
Horizon Discovery introduces Cas9 and dCas9-VPR stable cell lines
QC-validated cell lines promise to simplify and accelerate CRISPR gene editing workflows
Rentschler Biopharma licenses Horizon Discovery’s CHOSOURCE platform
Platform to complement Rentschler’s cell line development offering for difficult-to-express proteins
Horizon Discovery expands cell-based CRISPR screening services
Horizon Discovery has announced a new B cell screening service to support the development of therapeutics for immune system diseases
Horizon Discovery grants a multi-product use license of its GS knockout CHO K1 cell line to NGM Bio
Cell line to be used to support research and development of biotherapeutics across therapeutic areas
Horizon Discovery signs collaboration and license agreement with Mammoth Biosciences
Collaboration aims to develop the next-generation of engineered CHO cell lines and improve production of biotherapeutics
Life sciences round-up for 2019
Look back at some of the best life sciences content SelectScience has covered in 2019
